Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose

FDA sets PDUFA date of May 22, 2023 SANTA MONICA, Calif., Jan. (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT) today announced that the U.S. Food and Drug Administration (FDA